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tively. In addition, in the presence of 0.75 eccentricity, the maximum
principal stress value in the commissures was increased by 173%, 213%
and 149%, as compared to circular TAV expanded to 23, 21, and 19mm,
respectively.
CONCLUSIONS Computational models were developed to study the
synergistic impact of incomplete and eccentric TAV stent expansion on
leaﬂet stress distributions. Eccentric and incomplete stent deployment
induce localized high stress regions within the TAV leaﬂets. Increased
mechanical stress on TAV leaﬂets may lead to accelerated tissue
degeneration and diminished long-term valve durability.
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BACKGROUND The sequential implantation of a transcatheter heart
valve (THV) within a similar device, also known as valve-in-valve-in-
valve, will be an important concept in the future, considering patients
with elevated surgical risk and failed THVs within surgical aortic
valves (SAV). However, this procedure has not been studied in depth,
especially considering the reduction of effective oriﬁce area (EOA) and
the elevation of transvalvular gradients (DP). Our objective was to
evaluate the hydrodynamic performance of valve-in-valve-in-valve,
determining the therapeutic limits.
METHODS Using a pulse duplicator, three sets of valve-in-valve-in-
valve were tested. FDA speciﬁcations for cardiac output, mean arterial
pressure and heart rate variation were used. EOA and DP were
measured. First set was a 23mm surgical valve with two sequential
THV implants of 22mm and 20mm. Second set was a 25mm surgical
valve with two sequential THV implants of 24mm and 22mm. The last
set was a 25mm surgical valve with three sequential implants of
24mm, 22mm and 20mm.
RESULTS The results obtained from the three sets are represented on
Table 1.EOA (cm2) DP (mmHg)20mm THV within 22mm THV
within 23mm SAV0.97 12.822mm THV within 24mm THV
within 25mm SAV0.97 13.4620mm THV within 22mm THV
within 24mm THV within
25mm SAV0.86 15.32CONCLUSIONS The use of multiple THVs as an alternative to
repeated conventional aortic valve replacement can be considered
feasible after hydrodynamic testing. Satisfactory results can be ob-
tained with up to 22mm THVs. When a 20mm THV was needed, re-
sults were borderline to prohibitive, depending on whether it was the
2nd or 3rd implantation. The less-than-optimal results might be due to
device underexpansion.
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BACKGROUND There is limited data, especially from the US, on sex-
related differences with regards to patient characteristics and out-
comes with the CoreValve prosthesis. The objective of this study is to
compare the baseline characteristics and clinical outcomes in women
and men undergoing transcatheter aortic valve replacement with the
CoreValve prosthesis in the United States.
METHODS Patients used for this analysis include all patients who
underwent TAVR in any one of the 4 CoreValve US trials- the Cor-
eValve Pivotal extreme and high risk trials as well as the CoreValve
Continued Access extreme and high risk trials. Data from 3687 pa-
tients including 1708 women and 1979 men undergoing TAVR were
included for analysis.
RESULTS Women comprised 46% of the ﬁnal cohort and at baseline
had a higher STS score (9.6% vs. 8.3%). While there was no difference
in baseline NYHA classiﬁcation, women tended to have fewer cardiac
comorbidities and a lower rate of coronary artery disease including
fewer MIs, CABGs, and PCIs. Women were also less likely to have
peripheral vascular disease, a pre-existing pacemaker, or a prior
stroke. Conversely, women had increased frailty indices as measured
by KATZ ADL deﬁcits, walk times, and grip strength. At baseline
women had a higher mean gradient across the aortic valve (51.5 vs
44.3mmHg) and smaller EOA (0.66 vs. 0.79cm2). From a procedural
standpoint, women were slightly more likely to require alternative
access (21% vs 18.35%) and tended to receive smaller sized valves. The
30-day and 1-year outcomes are summarized in the table below.
CONCLUSIONS Women, who account for nearly half of the population
undergoing TAVR within the CoreValve US trials, tend to have fewer
cardiac comorbidities and increased frailty as compared to men. While
differences exist in procedural risks between men and women un-
dergoing TAVR with the CoreValve prosthesis, there was no difference
in 30-day or 1-year mortality.30 -days 1 yearMale
(N[1979)Female
(N[1708) P-valueMale
(N[1979)Female
(N[1708) P-valueAll-Cause Mortality, % 114 (5.8) 100 (5.9) 0.87 406 (24.1) 315 (21.3) 0.08Cardiovascular, % 109 (5.6) 98 (5.8) 0.74 305 (18.1) 242 (16.4) 0.23Stroke, % 79 (4.0) 95 (5.7) 0.02 129 (7.7) 141 (9.3) 0.05Major, % 42 (2.1) 60 (3.6) 0.01 72 (4.5) 86 (5.6) 0.04All-Cause Mortality or
Major Stroke, %142 (7.2) 140 (8.2) 0.22 434 (25.6) 353 (23.4) 0.32Bleed, % 615 (31.2) 728 (42.7) <0.0001 694 (36.7) 781 (46.8) <0.0001Life-Threatening/
disabling, %200
(10.2)244 (14.3) 0.0001 261 (14.3) 290 (17.9) 0.002Major Vascular
Complication, %96 (4.9) 165 (9.7) <0.0001 103 (5.3) 168 (9.9) <0.0001Acute Kidney Injury, % 222 (11.3) 175 (10.4) 0.38 222 (11.3) 175 (10.4) 0.38Myocardial Infarction,
%16 (0.8) 18 (1.1) 0.43 33 (2.1) 34 (2.4) 0.52Cardiac Tamponade, % 11 (0.6) 42 (2.5) <0.0001 15 (0.8) 43 (2.5) <0.0001New Permanent
Pacemaker
Implant, %453 (23.2) 311 (18.6) 0.0007 508
(27.0)346 (21.4) 0.0001KCCQ Overall
Summary Score
Change from
Baseline22.4 
27.422.4 
27.20.96 28.0 
28.128.9 
26.40.53
